These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 39230001)

  • 1. Investigation of Dual-Loaded Doxorubicin and Sorafenib Liposomes Co-Modified with Glycyrrhetinic Acid and Cell-Penetrating Peptide TAT.
    Su H; Tu Z; Jing L; Huang Y; Liu X; Yuan M
    Curr Drug Deliv; 2024 Sep; ():. PubMed ID: 39230001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
    Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
    Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
    Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N; Wu J; Wang W; Sun S; Sun M; Bian Y; Zhang H; Liu S; Yu G
    Drug Deliv Transl Res; 2024 Sep; 14(9):2386-2402. PubMed ID: 38236508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galactosylated Liposomes for Targeted Co-Delivery of Doxorubicin/Vimentin siRNA to Hepatocellular Carcinoma.
    Oh HR; Jo HY; Park JS; Kim DE; Cho JY; Kim PH; Kim KS
    Nanomaterials (Basel); 2016 Jul; 6(8):. PubMed ID: 28335269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA.
    Tian G; Pan R; Zhang B; Qu M; Lian B; Jiang H; Gao Z; Wu J
    Front Pharmacol; 2019; 10():4. PubMed ID: 30723405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery.
    Li L; Chen A; Liu B; Pan H; Yu Y; Liu Y
    Biomed Mater; 2022 May; 17(4):. PubMed ID: 35483344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy.
    Zhang J; Zheng Y; Xie X; Wang L; Su Z; Wang Y; Leong KW; Chen M
    Mol Pharm; 2017 Nov; 14(11):3644-3659. PubMed ID: 28994600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Yuan M; Qiu Y; Zhang L; Gao H; He Q
    Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
    Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
    ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma.
    Li X; Diao W; Xue H; Wu F; Wang W; Jiang B; Bai J; Lian B; Feng W; Sun T; Yu W; Wu J; Qu M; Wang Y; Gao Z
    Cancer Lett; 2020 Oct; 489():163-173. PubMed ID: 32592729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
    Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
    Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
    Yang B
    Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced anti-tumor therapy for hepatocellular carcinoma via sorafenib and KIAA1199-siRNA co-delivery liposomes.
    Yao Y; Zhao Q; Xu F; Yao T
    Saudi Pharm J; 2024 Sep; 32(9):102153. PubMed ID: 39211513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.